• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»mental health devices

FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?

By Pallavi Madhiraju on March 6, 2026   Medical Devices & Diagnostics  

FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?

Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.

Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment

By Pallavi Madhiraju on February 14, 2026   Medical Devices & Diagnostics  

Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment

Diamond Lake Clinic introduces EXOMIND for depression care. Find out what this shift means for neuromodulation, evidence standards, and mental health treatment models.

Recent Posts

  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
  • Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment
  • Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
  • Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
  • Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
  • Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes